.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
US Department of Justice
Boehringer Ingelheim
Deloitte
Express Scripts
Harvard Business School
Moodys
McKinsey
Johnson and Johnson
UBS

Generated: September 20, 2017

DrugPatentWatch Database Preview

SOMATULINE DEPOT Drug Profile

« Back to Dashboard

What is the patent landscape for Somatuline Depot, and when can generic versions of Somatuline Depot launch?

Somatuline Depot is a drug marketed by Ipsen Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has sixty-four patent family members in seventeen countries.

The generic ingredient in SOMATULINE DEPOT is lanreotide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lanreotide acetate profile page.

Summary for Tradename: SOMATULINE DEPOT

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list270
Drug Prices:see details
DailyMed Link:SOMATULINE DEPOT at DailyMed

Pharmacology for Tradename: SOMATULINE DEPOT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SOMATULINE DEPOT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,582,591 Delivery of solid drug compositions► Subscribe
6,142,972 Method and apparatus for the delivery of elongate solid drug compositions► Subscribe
5,837,276 Apparatus for the delivery of elongate solid drug compositions► Subscribe
5,660,846 Methods and apparatus for the delivery of solid drug compositions► Subscribe
5,616,123 Delivery of solid drug compositions► Subscribe
6,306,420 Methods and apparatus for the delivery of solid drug compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SOMATULINE DEPOT

Country Document Number Estimated Expiration
Portugal1270032► Subscribe
South Africa9507355► Subscribe
Denmark1157703► Subscribe
Japan4489186► Subscribe
Germany69535322► Subscribe
Spain2169762► Subscribe
Luxembourg91037► Subscribe
South Korea100491424► Subscribe
China1165477► Subscribe
Spain2295745► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SOMATULINE DEPOT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
037Luxembourg► Subscribe91037, EXPIRES: 20160511
2002 00032Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
AstraZeneca
Covington
QuintilesIMS
Julphar
Chubb
US Department of Justice
Mallinckrodt
Johnson and Johnson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot